Irisin in Fracture Healing and Bone-Defect Repair: A Systematic Review of Preclinical Evidence and Limited Human Biomarker Data
Current Issues in Molecular Biology · 16.11.2026 · 48 (11) · 1234
DOI: 10.3390/cimb48111234 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 16.11.2026. Verfasst von Alessandro Civinini und 4 weiteren Autor:innen. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Irisin, the cleaved extracellular portion of fibronectin type III domain-containing protein 5 (FNDC5), is a myokine implicated in muscle–bone crosstalk. Its role in bone repair has not been systematically appraised. This review synthesized preclinical and human evidence on irisin in fracture healing and bone-defect repair. MEDLINE/PubMed, Embase, the Cochrane Library, and Scopus were searched from inception to September 2026, following a prospectively registered protocol (OSF), with subsequent methodological amendments and PRISMA 2020. In vivo studies modulating irisin/FNDC5 in fracture or bone-defect models with a comparator, and human studies measuring circulating irisin during fracture healing, were eligible. Risk of bias was assessed with SYRCLE (animal studies) and the Newcastle–Ottawa Scale and QUIPS (human studies); certainty was rated with an adapted GRADE approach. Findings were synthesized narratively. Thirteen studies (14 reports) were included: 11 preclinical experiments (three fracture, eight bone-defect models) and two small observational human biomarker studies. All preclinical experiments administered recombinant irisin; none modulated FNDC5 directly. In fracture models, systemic (mice) or single local (rat) irisin was associated with larger or more mineralized callus and, in two studies, greater bending strength. In bone-defect models, local irisin delivery showed variable results, with statistically significant benefits over the carrier reported in four of eight experiments, although methodological limitations reduced confidence in these findings. Systemic irisin showed no benefit in the only defect experiment that tested it. Risk of bias was mostly unclear or high, and certainty of evidence was very low. No human study assessed whether circulating irisin was associated with radiological union, and no interventional human data exist. Preclinical data provide a preliminary, hypothesis-generating signal that exogenous irisin—particularly when delivered locally—may enhance bone repair. Therapeutic efficacy in humans has not been demonstrated.
Zitieren
APA
Civinini, A., Leggieri, F., Bianchi, A., Civinini, R., & Innocenti, M. (2026). Irisin in Fracture Healing and Bone-Defect Repair: A Systematic Review of Preclinical Evidence and Limited Human Biomarker Data. Current Issues in Molecular Biology, 48(11), 1234. https://doi.org/10.3390/cimb48111234
Vancouver
Civinini A, Leggieri F, Bianchi A, Civinini R, Innocenti M. Irisin in Fracture Healing and Bone-Defect Repair: A Systematic Review of Preclinical Evidence and Limited Human Biomarker Data. Current Issues in Molecular Biology. 2026;48(11):1234. doi:10.3390/cimb48111234
BibTeX
@article{Civinini2026,
author = {Civinini, Alessandro and Leggieri, Filippo and Bianchi, Alessandro and Civinini, Roberto and Innocenti, Matteo},
title = {Irisin in Fracture Healing and Bone-Defect Repair: A Systematic Review of Preclinical Evidence and Limited Human Biomarker Data},
journal = {Current Issues in Molecular Biology},
year = {2026},
volume = {48},
number = {11},
pages = {1234},
doi = {10.3390/cimb48111234}
}
EUVIMED